Feature

Foiling epilepsy in a brain at risk

See allHide authors and affiliations

Science  13 Dec 2019:
Vol. 366, Issue 6471, pp. 1304
DOI: 10.1126/science.366.6471.1304

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

About 30% of people who suffer a severe traumatic brain injury (TBI)—and a smaller percentage of people with a milder one—later develop epilepsy. Three years ago, a $21 million project spanning five countries took the first steps toward epilepsy prevention for brain-injured patients: searching for biomarkers that presage epilepsy and, in animals, drugs that prevent it. Physicians treating TBI could follow the lead of the first epilepsy prevention trial, which is testing the epilepsy drug vigabatrin in babies with a rare genetic syndrome called tuberous sclerosis complex that comes with a very high risk of the seizure disorder.

View Full Text

Stay Connected to Science